Efficacy of Human Papillomavirus Vaccines: A Systematic Quantitative Review

@article{Medeiros2009EfficacyOH,
  title={Efficacy of Human Papillomavirus Vaccines: A Systematic Quantitative Review},
  author={L{\'i}dia Rosi Medeiros and Daniela Dornelles Rosa and Maria In{\^e}s da Rosa and Mary Clarisse Bozzetti and Roselaine Ruviaro Zanini},
  journal={International Journal of Gynecologic Cancer},
  year={2009},
  volume={19},
  pages={1166-1176 - 1166-1176}
}
Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide. Two vaccines have been recently evaluated in randomized controlled trials: the bivalent vaccine for HPV 16 and 18 (Cervarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) and the quadrivalent vaccine for HPV 6, 11, 16, and 18 (Gardasil, Merck and Co, Inc, Whitehouse Station, NJ). We have performed a systematic review of all randomized controlled trials in which vaccines against HPV were compared with… Expand
Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review
TLDR
HPV vaccination in males is moderately effective against persistent anogenital HPV infection and high-grade anal intraepithelial lesions in studies where the population consists mainly of HPV-infected males, and supports a recommendation for vaccination of boys before the onset of sexual activity. Expand
[Efficacy of commercially available vaccines against HPV infection in women: a systematic review and meta-analysis].
TLDR
The HPV vaccines reduced the risk of precursor lesions of cervical cancer, presenting efficacy of 97% (95%CI: 90-99) for CIN 2 and 96% ( 95%CI): 89-99 forCIN 3, in the per protocol analysis. Expand
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
TLDR
Efficacy endpoints by initial HPV DNA statushrHPV negativeHPV vaccines reduce CIN2+, CIN3+, AIS associated with HPV16/18 compared with placebo in adolescent girls and women aged 15 to 26 and most women were under 26 years of age. Expand
Re: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
TLDR
None of the women in the trial developed cervical cancer during the approximately 63 000 women-years reported, and clinicians treated abnormalities identified during the tests with procedures known to be effective in preventing cervical cancer and thus vastly reduced the chances the women would get cervical cancer. Expand
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases
TLDR
Results show that the HPV-16/18 AS04-adjuvanted vaccine reduces HPV- 16/18 infection and associated cervical endpoints in women regardless of age, location, or sexual experience. Expand
Systemic Review for Efficacy of Human Papillomavirus Vaccines
TLDR
It is necessary to establish a reference laboratory and long-term follow-up monitoring system for the proper evaluation of HPV vaccines in Korea. Expand
Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis.
TLDR
HPV quadrivalent vaccine is efficacious in preventing AGW in men and women, according to a systematic review of randomized trials. Expand
Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews.
TLDR
Systematic reviews have found evidence that the available HPV vaccines are safe, effective, and efficacious against vaccine-type HPV infection and HPV-associated cellular changes, including precancerous and benign lesions. Expand
The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis
TLDR
Prophylactic, quadrivalent HPV vaccination can prevent GW in healthy women and men, therefore, it should be included in routine immunization programme. Expand
The two faces of human papillomavirus.
TLDR
The strongest evidence-base justifying immunization of men to prevent HPV-associated cancer will likely be from further trials examining protection against anogenital warts and anogenitals intraepithelial neoplasia in males, and no immunological marker of protection has been identified to date from the studies on long-term protection. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 88 REFERENCES
Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial
TLDR
The vaccine HPV16 L1 VLP provides high-level protection against persistent HPV16 infection and HPV16-related CIN2–3 for at least 3.5 years after immunization, likely to reduce risk for cervical cancer. Expand
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
TLDR
The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions. Expand
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
TLDR
In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group. Expand
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
TLDR
The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women in this randomized, placebo-controlled, doubleblind trial. Expand
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
TLDR
In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group. Expand
A controlled trial of a human papillomavirus type 16 vaccine.
TLDR
Administration of this HPV- 16 vaccine reduced the incidence of both HPV-16 infection and HPV-15-related cervical intraepithelial neoplasia, and immunizing HPV-14-negative women may eventually reduce the probability of cervical cancer. Expand
Papillomavirus vaccines in perspective
TLDR
An interim analysis of an international phase III study that assessed the effi cacy of an HPV 16/18 vaccine in women aged 15–25 years concludes that the vaccine may provide cross-protection against non-vaccine types. Expand
Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials
TLDR
Among women aged 15–25 years not previously infected with vaccine-type HPV strains, prophylactic HPV vaccination appears to be highly efficacious in preventing HPV infection and precancerous cervical disease. Expand
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
TLDR
A prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18, and this duration supports vaccination of adolescents and young adults. Expand
Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia
TLDR
There were no diagnoses of persistent HPV-16 infection among women who received all 3 doses of vaccine and completed 48 months of follow up (100% effective) and the level of anti-HPV-16 titers rose after each dose of vaccine. Expand
...
1
2
3
4
5
...